Background: Four oscillometric devices, including the Omron M6 Comfort, Omron HEM-7420, Withings BP-800, and Polygreen KP-7670, designed for self-blood pressure measurement (SBPM) were evaluated according to the European Society of Hypertension (ESH) International Protocol Revision 2010 in four separate studies. Methods: The four devices measure brachial blood pressure (BP) using the oscillometric method. The Withings BP-800 has to be connected to an Apple® iOS device such as an iPhone®, iPad®, or iPod®. The ESH International Protocol Revision 2010 includes a total number of 33 subjects. The difference between observer and device BP values was calculated for each measure. Ninety-nine pairs of BP differences were classified into three categories (≤5 mmHg, ≤10 mmHg, ≤15 mmHg). The protocol procedures were followed precisely in each of the four studies. Results: All four tested devices passed the validation process. The mean differences between the device and mercury readings were: −1.8±5.1 mmHg and −0.4±2.8 mmHg for systolic and diastolic BP, respectively, using the Omron M6 Comfort device; 2.5±4.6 mmHg and −1.2±4.3 mmHg for the Omron HEM-7420 device; −0.2±5.0 mmHg and 0.4±4.2 mmHg for the Withings BP-800 device; and 3.0±5.3 mmHg and 0.3±5.2 mmHg for the Polygreen KP-7670 device. Conclusion: Omron M6 Comfort, Omron HEM-7420, Withings BP-800, and Polygreen KP-7670 readings differing by less than 5 mmHg, 10 mmHg, and 15 mmHg fulfill the ESH International Protocol Revision 2010 requirements, and therefore are suitable for use by patients for SBPM, if used correctly.
1 November 2011 in Vascular Health and Risk Management
Background: Four oscillometric devices for self-measurement of blood pressure (SBPM) were evaluated according to the European Society of Hypertension (ESH) international protocol and its 2010 revision in four separate studies. The Omron® M2, Omron M3, and Omron M6 measure blood pressure (BP) at the brachial level, while the Omron R2 measures BP at the wrist level. Methods: The international protocol requires a total number of 33 subjects in which the validation is performed. The Omron M2 and Omron R2 were validated in 2009 according to the ESH international protocol, while the Omron M3 and Omron M6 were validated in 2010–2011 according to the 2010 ESH international protocol revision. The protocol procedures were followed precisely. Results: All four tested devices passed the validation process. The mean differences between the device and mercury readings were 2.7 ± 5.0 and –1.4 ± 3.2 mmHg for systolic and diastolic BP, respectively, using the Omron M2 device, and 1.7 ± 3.2 and –0.9 ± 2.6 mmHg using the Omron M3, 1.6 ± 2.9 and -0.9 ± 2.5 mmHg using the Omron M6, and –1.1 ± 4.8 and –0.9 ± 4.3 mmHg using the Omron R2. Conclusion: Readings from the Omron M2, Omron M3, Omron M6, and Omron R2, differing by less than 5, 10, and 15 mmHg, fulfill the ESH international protocol and its 2010 revision requirements. Therefore, each of these four devices can be used by patients for SBPM.
Three oscillometric devices for the self blood pressure measurement were evaluated according to the International Protocol of the European Society of Hypertension in three separate studies. The Omron M3 Intellisense and the Omron M2 Compact measures blood pressure (BP) at the brachial level; the Omron R3-I Plus measures BP at the wrist level. The International Protocol is divided into two phases and includes a total number of 33 participants on whom the validation is performed. In each study, and for each participant, four BP measurements were taken simultaneously by two observers using mercury sphygmomanometers alternately with three measurements with the tested device. The difference between the observers and the device BP values was calculated for each measurement. The 99 pairs of BP differences were classified into three categories (< or =5, < or =10, < or =15 mmHg). All three tested devices passed the first and second phase of the validation process. The mean differences between the device and mercury readings were 1.9+/-3.0 and -1.0+/-2.3 mmHg for systolic and diastolic BP, respectively, for the Omron M3 Intellisense device, 2.5+/-5.4 and -2.3+/-3.6 mmHg for the Omron M2 Compact device, and 1.4+/-4.5 and 0.8+/-4.6 mmHg for the Omron R3-I Plus device. Readings of the Omron M3 Intellisense, the Omron M2 Compact and the Omron R3-I Plus, differing by less than 5, 10, and 15 mmHg fulfill the International Protocol requirements and therefore can be used by patients for self blood pressure measurement.
1 January 2001 in American Journal of Cardiovascular Drugs
Arterial stiffness has been reported as an independent predictor of morbidity and mortality in different populations. Although measurement of pulse wave velocity is considered the gold standard for the assessment of arterial stiffness, it has several limitations: sensitivity to the blood pressure level, complexity of the measurement procedure, the bias of distance determination, etc. Recently, the cardio-ankle vascular index (CAVI), based on the beta index, measured using the VaSera device, has been introduced as an index of arterial stiffness from the origin of the aorta to the ankle. Theoretically, this new parameter and device present some advantages such as a relative independency from the blood pressure level at the time of measurement, high reproducibility and sensitivity, and a user-friendly device with a simplified procedure. In this article, several methodological aspects and clinical applications of CAVI have been reviewed: the principles of CAVI, its normal values according to age and gender, the thresholds used for diagnosis, the effect of cardiovascular risk factors and diseases on CAVI, its prognostic value and its eventual improvement after treatment with non-pharmacological intervention and various pharmacological agents.